Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study

Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study

Bibliographic Details
Main Authors: F. Saad, A.J. Armstrong, C. Ivanescu, H. Bhadauria, K. Ramaswamy, R. Morlock, B. Tombal
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S266616832033161X

Internet

http://www.sciencedirect.com/science/article/pii/S266616832033161X

Similar Items